Sellas Life Sciences: Rally Nears Pivotal Test as AML Trial Data Looms and Takeover Speculation Mounts

With 78 of 80 survival events recorded, Sellas nears REGAL Phase 3 unblinding. Stock up 600% but overbought; hazard ratio ?0.636 is key. Analysts warn of potential collapse if data disappoints.

The clock is ticking for Sellas Life Sciences. With 78 of the 80 required survival events now recorded in the REGAL Phase 3 study, the biotech is on the cusp of unblinding its most critical data point yet. The stock, which has surged more than 600% over the past twelve months, closed Thursday at €13.00 — just off the 52-week high of €15.25 set three days earlier. For investors who have ridden this breathtaking rally, the coming weeks represent the moment of truth.

All eyes are on a single metric: the hazard ratio. To prove that Galinpepimut-S (GPS) improves overall survival in acute myeloid leukemia patients compared with standard therapy, Sellas needs a hazard ratio of 0.636 or better. The company’s current market capitalisation of €2.54 billion is essentially a bet on that number. Fall short, and analysts warn the stock could collapse toward their average target of €8.74 — or lower.

Technical Warnings Flash Amid Euphoria

The rally has been nothing short of extraordinary. The stock has climbed roughly 84% in the past 30 days alone, pushing it 85% above its 50-day moving average. The 14-day relative strength index now stands at 73.7, deep in overbought territory. Meanwhile, trading volume has failed to keep pace with the price move. At the recent push toward the year’s high, shares changed hands at roughly average daily levels — a classic warning sign that the breakout may lack conviction.

Institutional investors appear to be taking advantage. The inflow ratio dropped to 0.47, suggesting that professional money managers are selling into strength while retail buyers continue to pile in. The annualised 30-day volatility of 123% underscores just how wild the ride has been.

Corporate Moves Fuel Takeover Talk

Adding to the drama, Sellas recently amended its executive contracts to include change-of-control clauses. The market has seized on the move as a signal that management is preparing for a potential sale or partnership should the data prove positive. A larger pharma company would likely be attracted to GPS’s potential, and the provisions would shield executives financially in such a scenario.

The company’s balance sheet provides a cushion. At the end of the first quarter, Sellas held €107.1 million in cash — enough to fund operations well beyond the data readout without an immediate capital raise. Those funds also support the development of SLS009, a CDK9 inhibitor in Phase 2 for frontline AML, with results expected in the fourth quarter of 2026.

The Bear Case: Everything Priced In?

Sceptics counter that the rally has already discounted a positive outcome. At €13.00, the stock trades 32.8% above the consensus analyst price target of €8.74 — leaving little room for upside even if the data hits the mark. The 52-week low sits at €1.22, underscoring the speculative premium that has been built.

Some also question whether the long wait for the 80th event is a good sign. While management has argued that the extended survival in the GPS arm suggests the drug is working, bears point out that it could equally reflect unexpectedly good results in the control group — which would make it harder for GPS to reach statistical significance. Without a positive survival readout, Sellas has no approved product and no other late-stage programme to fall back on.

What Comes Next

The formal announcement of the 80th event and the subsequent database lock are expected in the coming weeks, likely still within the third quarter. If the data come in at or below the critical hazard ratio threshold, a sharp correction toward €8.74 or below is likely. The 200-day moving average at €3.67 would become the next major support level in a worst-case scenario.

A successful readout, on the other hand, could propel shares back toward the €15.25 peak and beyond, with a potential takeover or licensing deal adding further upside. For now, the stock sits 89.8% above its 50-day average of €6.85, a stretched position that leaves little margin for disappointment. The next few weeks will determine whether the rally was built on substance or speculation.